Pfizer leads busy bond week; GSK gets green light for U.K. expansion;


@FiercePharma: Roche unveils more plans for plant expansions in Switzerland. Story | Follow @FiercePharma

@TracyStaton: If AstraZeneca were Harry Potter, would that make Pfizer Voldemort? More | Follow @TracyStaton

@EricPFierce: China forewarns drugmakers. It's not messing around when it comes to bribery as a sales tool. More | Follow @EricPFierce


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

@CarlyHFierce: First, bribery. Now, China floats tax-evasion accusations against GlaxoSmithKline. News | Follow @CarlyHFierce

> Pfizer ($PFE) is leading a busy week of bond sales, issuing $4.5 billion. Report

> GlaxoSmithKline ($GSK) has won approval for its £100 million ($168 million) plans to expand a pharmaceutical plant in Worthing, U.K. More

> Endo ($ENDP) has acquired from Zogenix ($ZGNX) the rights to its Sumavel DosePro, a needle-free delivery system for migraine treatment. Release

> Forest Labs ($FRX) is selling its building in Commack, NY. Story

> Reckitt Benckiser, looking for deal approval, has applied to New Zealand's Commerce Commission seeking clearance to acquire Johnson & Johnson's ($JNJ) K-Y brand and product assets. More

> Indonesian herbal medicine maker Sido Muncul is buying pharmaceutical firm PT Berlico Mulia Farma for about 150 billion rupiah ($13.1 million). More

Medical Device News

@FierceMedDev: Water Street plans to grow a German specialty Dx company into a major player, through investment and M&A. ICYMI from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: It's official: Alere is spinning off its diagnostics biz. More | Follow @VarunSaxena2

@MichaelGFierce: From Harvard Research: Herpes-loaded stem cells used to kill brain tumors. More | Follow @MichaelGFierce

@EmilyWFierce: Gelesis brought in $12M for superabsorbent hydrogel technology that swells in the stomach to treat obesity. More from MedCityNews | Follow @EmilyWFierce

> Acufocus gears up for FDA scrutiny on corneal implant. Item

> It's official: Alere is spinning off its diagnostics biz. Article

> CMS closer to coverage for Abbott's MitraClip. More

Biotech News

@FierceBiotech: Why did Pfizer's big fiesta for palbociclib fizzle? Story | Follow @FierceBiotech

@JohnCFierce: Elotuzumab: Bristol-Myers nabs another 'breakthrough' cancer drug title. More | Follow @JohnCFierce

@DamianFierce: From yesterday: The redacted bit of Pfizer's letter sort of spells out their passive-aggressive strategy. Image | Follow @DamianFierce

@EmilyMFierce: Scientists can have an impact on the antibiotic crisis by engaging the public and talking to media, says Ian Lipkin. | Follow @EmilyMFierce

> AstraZeneca slaps down Pfizer's 'final' $119B takeover bid. More

> Boehringer, InterMune wow IPF field with a slate of groundbreaking trial data. Story

> Another animal health biotech plots an IPO. Item

CRO News

> WuXi wraps up construction on a new biologics shop. Item

> Bayer agrees to share trial data, but not without a list of caveats. Article

> PRA amps up its biologics footprint amid industry shift. Story

> Evotec's hybrid CRO approach pays off in Q1. More

> WuXi scores more double-digit growth amid its global expansion. Report

Biotech IT News

> Venter nabs AstraZeneca's R&D IT chief for Human Longevity. News

> Bayer, Boehringer extend access to clinical trial data. Item

> NIH lays out up to $20B in IT spending over coming decade. More

> HCL Tech adds Novartis to roster of Big Pharma clients. Story

> GSK signs up to access Metabolon's bioinformatics tools. Article

And Finally... Which is better at detecting cancer, a laboratory or a Labrador retriever? It could be the latter. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.